Overview

A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

A total of 120 patients will be entered in this study to assess the safety and efficacy of enteric coated sevelamer (ECS) to lower LDL cholesterol. Patients will be randomized into two active treatment groups, two placebo groups and one active control group.

Phase:

Phase 2

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Collaborator:

Manipal Acunova Ltd.

Treatments:

Colesevelam Hydrochloride
Sevelamer